Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference10 articles.
1. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis;Kanie;Cochrane Database Syst Rev,2021
2. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors;Scheen;Circ Res,2018
3. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications;Brown;Lancet,2021
4. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records;Xie;Lancet Diabetes Endocrinol,2023
5. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs;Giugliano;Cardiovasc Diabetol,2022
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献